General remarks on cephalosporins and semisynthetic penicillins — aspects of clinical administration W. Marget OriginalPaper Pages: S241 - S243
The meaning of the development of flomoxef and clinical experience in Japan M. ItoT. Ishigami OriginalPaper Pages: S253 - S257
Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef H. Grimm OriginalPaper Pages: S258 - S263
In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin) A. BauernfeindS. SchweighartR. Jungwirth OriginalPaper Pages: S264 - S275
In vitro activity of flomoxef and cefazolin in combination with vancomycin C. SimonMaria Simon OriginalPaper Pages: S276 - S278
The in vitro activity of flomoxef compared to four other cephalosporins and imipenem P. M. ShahH. Knothe OriginalPaper Pages: S279 - S283
Effect of flomoxef on blood coagulation and alcohol metabolism K. UchidaT. Matsubara OriginalPaper Pages: S284 - S295
Pharmacokinetics and hemostasis following administration of a new, injectable oxacephem (6315-S, flomoxef) in volunteers and in patients with renal insufficiency K. AndrassyJ. KoderischK. Hirauchi OriginalPaper Pages: S296 - S302